INS and cancer: Although PPARγ activators, such as thiazolidinediones, have shown considerable efficacy in enhancing insulin responsiveness in individuals with type 2 diabetes, their clinical use has been limited due to multiple side effects, such as weight gain, fluid accumulation, bone fractures, and a heightened cancer risk [82].